: iStockAnalyst.com Symbols Feed

Searching For Positive Catalysts

Mon, 16 Jun 2008 13:52:17 GMT

Good morning. Premarket futures have a slight negative bias this morning.[More...]

Marshall Edwards, Inc. Receives Nasdaq Notice of Minimum Bid Price Non-Compliance

Tue, 22 Sep 2009 13:47:00 GMT

Marshall Edwards, Inc. (NASDAQ: MSHL), a specialist oncology company focusing on the clinical development of novel anti-cancer therapeutics, today announced that on September 16, 2009, as management expected, the Company received a letter from The Nasdaq Stock Market notifying the Company that for the last 30 consecutive business days the bid price of the Company's common stock closed below the minimum $1.00 per share requirement for continued inclusion on the Nasdaq Global Market under Nasdaq Rule 5450(a)(1).
In order to regain compliance, shares of the Company's common stock must maintain a minimum bid closing price of at least $1.00 per share for a minimum of ten consecutive business days during the grace period.
About Marshall Edwards, Inc.

[More...]

Marshall Edwards Licenses the Investigational Anti-Cancer Compound NV-128 From Novogen Limited

Wed, 05 Aug 2009 12:00:00 GMT

NEW CANAAN, CT and SYDNEY, AUSTRALIA -- -- 08/05/09 -- Novogen Limited and Marshall Edwards, Inc. have concluded a license agreement for Marshall Edwards to develop and commercialize the oncology compound NV-128.[More...]

Novogen Director Retires

Thu, 30 Jul 2009 11:56:00 GMT

SYDNEY, AUSTRALIA -- -- 07/30/09 -- The Board of Novogen Limited has received and accepted the resignation of Mr. Peter B. Simpson as a Director of the Company.[More...]

Integrity Media Identifies Market Actives: IFSL, GRVY, NVGN, AMGN, THC, DCP, FDO

Wed, 08 Jul 2009 16:50:00 GMT

LAS VEGAS, July 8 /PRNewswire/ -- Integrity Media has issued a Market Actives List for today, specifically encouraging investors of the following equities to closely monitor trading activity for Ideal Financial Solutions (Pink Sheets: IFSL) - which announced this morning that company revenues doubled in the second quarter, GRAVITY Co., Ltd. (Nasdaq: GRVY), Novogen Limited (Nasdaq: NVGN), Amgen Inc. (Nasdaq: AMGN), Tenet Healthcare Corporation (NYSE: THC), DynCorp International Inc. (NYSE: DCP), and Family Dollar Stores (NYSE: FDO).
Register to receive exclusive information on emerging public companies at: http://smallcapsentinel.com/register
A report has been released regarding Ideal Financial Solutions.

[More...]

Integrity Media Identifies Market Actives: IFSL, GRVY, NVGN, AMGN, THC, DCP, FDO

Wed, 08 Jul 2009 15:51:00 GMT

LAS VEGAS, July 8 /PRNewswire/ -- Integrity Media has issued a Market Actives List for today, specifically encouraging investors of the following equities to closely monitor trading activity for Ideal Financial Solutions (Pink Sheets: IFSL) - which announced this morning that company revenues doubled in the second quarter, GRAVITY Co., Ltd. , Novogen Limited , Amgen Inc. , Tenet Healthcare Corporation , DynCorp International Inc. , and Family Dollar Stores .
Register to receive exclusive information on emerging public companies at: http://smallcapsentinel.com/register
A report has been released regarding Ideal Financial Solutions.

[More...]

Researchers Discover That Phenoxodiol Kills Rapidly Proliferating T-Cells

Tue, 07 Jul 2009 11:56:00 GMT

NEW CANAAN, CT and SYDNEY, AUSTRALIA -- -- 07/07/09 -- Researchers at the Malaghan Institute of Medical Research in Wellington, New Zealand have found that abnormally proliferating human T-cells, rapidly dividing cancer cells such as primary myeloid and lymphoid leukemic blast cells undergo programmed cell death when exposed briefly to the investigational anti-tumor drug phenoxodiol.[More...]

Independent Data Monitoring Committee Reviews Marshall Edwards, Inc.'s Arrangements for Data Analysis of the Ovature Trial

Wed, 17 Jun 2009 12:25:00 GMT

NEW CANAAN, CT -- -- 06/17/09 -- The Independent Data Monitoring Committee created to oversee the conduct of the Phase III OVArian TUmor REsponse Trial, which convened during the recent Annual Meeting of the American Society of Clinical Oncology, considered the data accumulated to date and reviewed the arrangements announced by the Company for early termination of patient enrollment into the study.[More...]

Novogen's NV-128 Targets the mTOR Pathway to Block Differentiation and Induce Cell Death in Ovarian Cancer Stem Cells

Mon, 20 Apr 2009 11:56:00 GMT

NEW CANAAN, CT and SYDNEY, AUSTRALIA -- -- 04/20/09 -- Data presented yesterday at the Annual Meeting of the American Association for Cancer Research in Denver has demonstrated that NV-128, a Novogen, Limited synthetic isoflavonoid compound, not only induces cell death in Ovarian Cancer Stem Cells , but also blocks their differentiation into structures which are required to support tumor growth.[More...]

Marshall Edwards, Inc., to Undertake Analysis of Ovature Trial

Tue, 14 Apr 2009 12:15:00 GMT

NEW CANAAN, CT and SYDNEY, AUSTRALIA -- -- 04/14/09 -- Marshall Edwards, Inc., today announced that it will be undertaking an un-blinded analysis of the data from its Phase III international, multicenter clinical study known as 'Ovature' .[More...]

Board Changes at Novogen Limited Announced - Mar 23 2009 12:55PM

Mon, 23 Mar 2009 16:50:00 GMT

Novogen Limited (ASX: NRT) (NASDAQ: NVGN) is pleased to announce the appointment of Mr. William D. Rueckert to its Board of Directors.
The advantage for Novogen of Mr. Rueckert becoming a director is that he is already familiar with the group, having been a director for two years on the boards of subsidiaries, Glycotex and Marshall Edwards, and brings considerable U.S. based commercial experience.
Mr. Rueckert is the Managing Member of Oyster Management Group, LLC and is a director of Glycotex, Inc., an 83 percent owned unlisted subsidiary of Novogen Limited.

[More...]